NervGen Pharma Corp. (9UA.F)

1,6300 -0,0400 (-2,40%) Börsenschluss: 03:29PM CEST

NervGen Pharma Corp.

112-970 Burrard Street
Unit 1290
Vancouver, BC V6Z 2R4
Canada
778 731 1711
https://www.nervgen.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Michael Kelly	CEO, President & Director	492,5k	N/A	1966
Mr. William Joseph Radvak BASc	Co-Founder & Advisor	39,91k	N/A	1963
Dr. Harold Martin Punnett D.M.D.	Co-Founder & Independent Director	N/A	N/A	N/A
Mr. William J. Adams C.A., CPA, CA, CPA	CFO & Corporate Secretary	287,14k	N/A	1962
Dr. Daniel D. Mikol M.D., Ph.D.	Chief Medical Officer	528,2k	N/A	N/A
Mr. Brian McAlister	Co-Founder & Advisor	N/A	N/A	N/A
Dr. Charles V. Olson D.Sc.	Senior Vice President of Technical Operations	N/A	N/A	1957
Ms. Elizabeth Eberhardt B.Sc.	Senior Vice President of Program Management	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in EUR.

Beschreibung

NervGen Pharma Corp., together with its subsidiaries, engages in the discovery, development, and commercialization of pharmaceutical treatments for medical conditions related to nervous system damage. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), multiple sclerosis, and Alzheimer's disease. It has a licensing agreement with Case Western Reserve University to research, develop, and commercialize a patented technology with therapeutic potential for spinal cord injury and other conditions associated with nerve damage. The company was incorporated in 2017 and is based in Vancouver, Canada.

Corporate Governance

NervGen Pharma Corp.s ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.